Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24995376 | 0.77 | CCNT1 (0.40) | — | |
| SCHEMBL20109750 | 0.67 | PDE10A (0.32) | NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL24759409 | 0.65 | KDM5B (0.45) | NOS3NOS1NOS2KDM5BHRH3 | |
| SCHEMBL24371169 | 0.65 | HTR4 (0.42) | ALDH1A1 | |
| SCHEMBL11652919 | 0.64 | HTR4 (0.41) | ALDH1A1 | |
| SCHEMBL6289321 | 0.62 | KMT2A (0.33) | NOS3NOS1NOS2ALDH1A1KMT2A | |
| SCHEMBL24470101 | 0.62 | PDE2A (0.38) | NOS3NOS1NOS2KDM5BMEN1 | |
| SCHEMBL20088527 | 0.62 | HTR4 (0.32) | — | |
| SCHEMBL24175233 | 0.62 | CCNT1 (0.40) | — | |
| SCHEMBL24995358 | 0.62 | ABL1 (0.36) | NOS3NOS1NOS2KDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | MAVS, ZC3HAV1, SARS1 | NOS3 2970/4885NOS1 3162/4885NOS2 3070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.